NovoCure received FDA approval on February 11, 2026 for its Optune Pax® device in adult patients with locally advanced pancreatic cancer, marking the first new treatment for the indication in nearly three decades.
The approval was based on the Phase 3 PANOVA‑3 trial, which enrolled 571 patients and demonstrated a median overall survival of 16.2 months versus 14.2 months for chemotherapy alone, along with a statistically significant extension of time to pain progression when Optune Pax was combined with gemcitabine and nab‑paclitaxel.
The approval expands NovoCure’s Tumor Treating Fields platform beyond its established glioblastoma indication and opens a new revenue stream. The company has set a goal of a 7‑to‑10‑fold expansion of its oncology platform by 2026, and the pancreatic indication is a key milestone toward that objective.
Financially, NovoCure reported net revenues of $655.4 million for 2025, up 8% year‑over‑year, and $167.2 million for Q3 2025, also an 8% increase. Gross margin fell to 73% in Q3 2025 from 77% the prior year, reflecting early rollout costs and tariff impacts, while the company continues to invest heavily in R&D and commercial launches, targeting adjusted EBITDA breakeven by 2027.
In its Q3 2025 earnings call, CEO Ashley Cordova said, 'With four indications expected in market by year‑end 2026, we are well on our way to becoming a platform therapy company — and we remain sharply focused on reaching profitability and expanding patient impact.' Executive Chairman William Doyle added, 'We ended the third quarter with 4,277 GBM patients on therapy, our largest patient count to date,' and reiterated confidence in the company’s plans to achieve profitability. CEO Frank Leonard noted, 'Novocure exits 2025 having achieved record annual revenue, providing the financial strength to execute on the exciting growth opportunities we have in 2026.' Investigator Vincent Picozzi highlighted the clinical impact, stating, 'In the Phase 3 PANOVA‑3 trial, treatment with Optune Pax resulted in a statistically significant improvement in overall survival without adding to the systemic side effects commonly associated with existing therapies. It also significantly extended time to pain progression, helping to preserve overall quality of life, which is a priority when I am treating patients living with pancreatic cancer. With FDA approval, Optune Pax has the potential to be practice changing for the treatment of patients with locally advanced pancreatic cancer.'
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.